Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results
November 12, 2019 7:57 AM ESTFunding expected to extend Companys cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat; MTPCs positive Phase 3 data show vadadustats effect on hemoglobin was sustained through to 52 weeks; Auryxia ® (ferric citrate) revenue increases to $30.0 million for Q3FY19, up 13% from Q3FY18; and, Company hosts call to discuss financial results and recent business highlights
CAMBRIDGE, Mass.--(BUSINESS... More
